Structures by: Chibale K.
Total: 27
(1S,2S,7R,8S,9R)-8-hydroxymethyl-10,12-dioxatricyclo- (7.2.1.027)dodec-4-ene
C11H16O3
Organic & Biomolecular Chemistry (2009) 7, 17 3527-3536
a=7.475(1)Å b=8.234(1)Å c=16.061(2)Å
α=90.00° β=90.00° γ=90.00°
7-chloro-quinolin-4-yl)-(2-dimethylaminomethyl- ruthenocen-1-ylmethyl)-amine
C23H24ClN3Ru
J. Chem. Soc., Dalton Trans. (2002) 23 4426
a=7.83220(10)Å b=12.61760(10)Å c=21.1164(2)Å
α=90.00° β=92.5260(10)° γ=90.00°
C18H23FN4O2
C18H23FN4O2
MedChemComm (2019) 10, 3 450-455
a=13.6252(16)Å b=10.5144(12)Å c=12.6246(13)Å
α=90° β=96.075(2)° γ=90°
Isoruthenoquine monohydrate
C23H26ClN3ORu
J. Chem. Soc., Dalton Trans. (2002) 23 4426
a=26.463(5)Å b=9.2209(18)Å c=21.907(4)Å
α=90.00° β=126.42(3)° γ=90.00°
7-Chloro-4-[2-(N'-substituted aminomethyl)-N-ferrocenylmethyl-(aminopropyl)trimethylsilane]quinoline
C27H34ClFeN3Si
Dalton transactions (Cambridge, England : 2003) (2016) 45, 47 19086-19095
a=6.6872(6)Å b=7.7098(7)Å c=25.388(2)Å
α=92.4700(10)° β=94.337(2)° γ=95.214(2)°
7-Chloro-4-[2-(N'-substituted aminomethyl)-N-ferrocenylmethyl-(amino-2,2?-dimethylpropyl)]quinoline
C26H30ClFeN3
Dalton transactions (Cambridge, England : 2003) (2016) 45, 47 19086-19095
a=8.6284(12)Å b=10.9159(15)Å c=26.353(4)Å
α=83.680(3)° β=84.639(3)° γ=73.336(3)°
N-(7-chloro-quinolin-4-yl)-N'-(2-dimethylaminomethylferrocen-1-ylmethyl) -ethane-1,2-diamine
C25H29ClFeN4
Dalton Transactions (2003) 15 3046
a=10.7012(3)Å b=16.2573(4)Å c=13.7853(3)Å
α=90.00° β=92.7270(10)° γ=90.00°
7-chloroquinolin-4-yl)-N'-(1'-dimethylaminomethylferrocen-1- ylmethyl)-amine
C23H26ClFeN3O
Dalton Transactions (2003) 15 3046
a=26.3704(2)Å b=9.2289(3)Å c=21.7319(4)Å
α=90.00° β=127.2210(10)° γ=90.00°
C23H29Cl2N3ORuS
C23H29Cl2N3ORuS
Dalton transactions (Cambridge, England : 2003) (2013) 42, 13 4677-4685
a=12.1626(9)Å b=12.8067(9)Å c=17.0022(13)Å
α=90.00° β=109.213(2)° γ=90.00°
C42H48Cl10Ir2N2O4
C42H48Cl10Ir2N2O4
Dalton transactions (Cambridge, England : 2003) (2014) 43, 2 513-526
a=11.572(2)Å b=20.505(4)Å c=21.518(4)Å
α=90.00° β=103.65(3)° γ=90.00°
C42H48Cl10N2O4Rh2
C42H48Cl10N2O4Rh2
Dalton transactions (Cambridge, England : 2003) (2014) 43, 2 513-526
a=11.5800(6)Å b=20.4163(11)Å c=21.4575(11)Å
α=90.00° β=102.7920(10)° γ=90.00°
C22H26AuBr2ClN8S2
C22H26AuBr2ClN8S2
Dalton transactions (Cambridge, England : 2003) (2010) 39, 10 2697-2700
a=11.846(2)Å b=10.358(2)Å c=24.577(5)Å
α=90.00° β=101.89(3)° γ=90.00°
C22H24AuCl5N8S2
C22H24AuCl5N8S2
Dalton transactions (Cambridge, England : 2003) (2010) 39, 10 2697-2700
a=11.776(2)Å b=10.658(2)Å c=24.515(5)Å
α=90.00° β=96.79(3)° γ=90.00°
MMP
C18H17N3O3S
CrystEngComm (2014) 16, 26 5781
a=14.0063(3)Å b=16.8616(4)Å c=7.8007(5)Å
α=90.00° β=105.4020(10)° γ=90.00°
3-6(-Methoxypyridin-3-yl)-5-(4-methylsulfonylphenyl)- pyridine-2-amine. hexanedioic acid
2(C18H17N3O3S1),C6H10O4
CrystEngComm (2014) 16, 26 5781
a=10.4542(7)Å b=10.7365(7)Å c=19.2796(12)Å
α=92.4070(10)° β=96.173(2)° γ=105.2470(10)°
3-6(-Methoxypyridin-3-yl)-5-(4-methylsulfonylphenyl)- pyridine-2-amine.(E)-butenedioate methanolate
C18H18N3O3S,C4H3O4,C1H4O
CrystEngComm (2014) 16, 26 5781
a=5.411(2)Å b=11.572(5)Å c=18.486(8)Å
α=87.456(8)° β=89.447(7)° γ=84.076(8)°
007 oxalic acid hydrate salt
C18H18N3O3S,0.5(C2O4),4(H2O)
CrystEngComm (2014) 16, 26 5781
a=18.581(2)Å b=5.1754(7)Å c=23.326(3)Å
α=90.00° β=106.774(2)° γ=90.00°
3-6(-Methoxypyridin-3-yl)-5-(4-methylsulfonylphenyl)- pyridine-2-amine. 2H-1lamda6,2-benzothiazol-1,1,3-trione salt hydrate
C18H18N3O3S1,C7H3N1O3S1,2.48(H2O1)
CrystEngComm (2014) 16, 26 5781
a=13.4221(6)Å b=16.7460(8)Å c=25.6251(12)Å
α=90.00° β=99.4440(10)° γ=90.00°
3-6(-Methoxypyridin-3-yl)-5-(4-methylsulfonylphenyl)- pyridine-2-amine. 2-hydroxybenzoate salt hydrate
C18H18N3O3S,C7H5O3S,H2O1
CrystEngComm (2014) 16, 26 5781
a=13.2320(8)Å b=11.6031(7)Å c=16.5449(10)Å
α=90.00° β=110.9770(10)° γ=90.00°
3-6(-Methoxypyridin-3-yl)-5-(4-methylsulfonylphenyl)- pyridine-2-amine. octanedioate salt
C18H18N3O3S1,C8H13O4
CrystEngComm (2014) 16, 26 5781
a=5.4192(7)Å b=12.1987(15)Å c=19.705(3)Å
α=75.627(2)° β=88.814(2)° γ=89.651(2)°
C28H40Cl5FeN3RuSSi
C28H40Cl5FeN3RuSSi
Dalton transactions (Cambridge, England : 2003) (2015) 44, 5 2456-2468
a=13.8986(3)Å b=22.6091(4)Å c=11.4831(3)Å
α=90.00° β=103.4820(10)° γ=90.00°
C25H30ClFeN3Si
C25H30ClFeN3Si
Organometallics (2014) 33, 17 4345
a=8.598(2)Å b=11.434(3)Å c=13.384(4)Å
α=84.800(9)° β=77.444(7)° γ=73.074(8)°
C27H22Cl2N3PPtS,0.5(C4H12O2S2),C2H6OS
C27H22Cl2N3PPtS,0.5(C4H12O2S2),C2H6OS
Organometallics (2012) 31, 16 5791
a=15.9511(4)Å b=9.2259(2)Å c=23.0990(6)Å
α=90.00° β=90.00° γ=90.00°
C36H28Cl8N12Pt4S4,3(C2H6OS)
C36H28Cl8N12Pt4S4,3(C2H6OS)
Organometallics (2012) 31, 16 5791
a=14.7265(6)Å b=30.6788(14)Å c=14.2547(6)Å
α=90.00° β=111.9020(10)° γ=90.00°
C15H19Cl2N6PPtS
C15H19Cl2N6PPtS
Organometallics (2012) 31, 16 5791
a=19.176(4)Å b=6.0493(12)Å c=17.977(4)Å
α=90.00° β=114.13(3)° γ=90.00°
C15H21ClN2Si
C15H21ClN2Si
Organometallics (2013) 32, 1 141
a=12.3956(12)Å b=13.0995(13)Å c=19.6103(18)Å
α=90.00° β=90.00° γ=90.00°
C23H33Cl2N2RhSi
C23H33Cl2N2RhSi
Organometallics (2013) 32, 1 141
a=32.1880(12)Å b=10.7870(2)Å c=15.5010(6)Å
α=90.00° β=115.3050(10)° γ=90.00°